News

Investor Webinar: 2020 Antimicrobial Resistance (AMR) Benchmark

On 28 and 29 January, the Access to Medicine Foundation will host an investor webinar about the newly published 2020 AMR Benchmark. It will provide investors with an introduction about the materiality of AMR for the pharmaceutical industry and present the results from the most recent independent comparison of how 30 different pharmaceutical companies are responding to rising rates of drug-resistant infections.

Read More...

2020 Antimicrobial Resistance Benchmark launches on 21 January

The 2nd AMR Benchmark report will go live on Tuesday 21 January. It will give a reality check on how the biggest players in anti-infectives markets are responding to drug resistance and access challenges. After launch, the research will first be presented in a dedicated session at the 2020 WEF Annual Meeting in Davos.

Read More...

WHO issues new reports on the clinical and preclinical pipeline on antibacterial agents

Declining private investment and lack of innovation in the development of new antibiotics are undermining efforts to combat drug-resistant infections, says the World Health Organization (WHO).

Read More...

World Bank releases report on antimicrobial resistance

In early October, the World Bank Group released a report on antimicrobial resistance. By looking at several country-based case studies, along with the growing literature on AMR, this report outlines factors both helping and burdening interventions towards controlling AMR, especially in low- and middle-income countries (LMICs).

Read More...

FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance

The U.S. Food and Drug Administration today approved Fetroja (cefiderocol), an antibacterial drug for treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including kidney infections caused by susceptible Gram-negative microorganisms, who have limited or no alternative treatment options.

Read More...

Open-access database helps scientists identifying urgently needed new antibiotics

For more than a year now, a publically accessible database is available enabling scientists to share data and insights, learn from past research, and generate new insights into how molecules interact with bacteria. Several pharmaceutical companies (such as Novartis and Achaogen) have uploaded research data from their discontinued candidate antibiotics to the database.

Read More...